Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Gerd Bönner, Bernhard Landers & Peter Bramlage. (2011) Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Vascular Health and Risk Management 7, pages 85-95.
Read now
Read now
Zeeshan Khawaja & Christopher S Wilcox. (2011) An overview of candesartan in clinical practice. Expert Review of Cardiovascular Therapy 9:8, pages 975-982.
Read now
Read now
Thomas Mengden, Sakir Uen & Peter Bramlage. (2009) Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility. Vascular Health and Risk Management 5, pages 1043-1058.
Read now
Read now
Joel M. Neutel, Stanley S. Franklin, Amitabha Bhaumik, Pablo Lapuerta & Suzanne Oparil. (2009) Safety and Tolerability of Fixed-Dose Irbesartan/Hydrochlorothiazide for Rapid Control of Severe Hypertension. Clinical and Experimental Hypertension 31:7, pages 572-584.
Read now
Read now
Articles from other publishers (11)
P. K. Karnakova, T. N. Komarov, O. A. Archakova, D. S. Shchelgacheva, A. A. Aleshina, N. S. Bagaeva, P. A. Karpova & I. E. Shohin. (2021) Simultaneous Determination of Candesartan and Hydrochlorothiazide in Human Plasma by HPLC-MS/MS. Drug development & registration 10:4, pages 177-189.
Crossref
Crossref
E. V. Sayutina. (2018) Fixed combinations in modern hypertension treatment algorithms. Cardiovascular Therapy and Prevention 17:6, pages 86-94.
Crossref
Crossref
Bhupinder Singh, Rama S. Lokhandae, Ashish Dwivedi, Sandeep Sharma & Naveen Dubey. (2014) Improved simultaneous quantitation of candesartan and hydrochlorthiazide in human plasma by UPLC–MS/MS and its application in bioequivalence studies. Journal of Pharmaceutical Analysis 4:2, pages 144-152.
Crossref
Crossref
Peter Bramlage, Hartmut Buhck & Claudia Zemmrich. (2014) Candesartan Cilexetil 32 mg/Hydrochlorothiazide 25 mg in Unselected Patients with High or Very High Cardiovascular Risk: Efficacy, Safety, and Metabolic Impact. Clinical Drug Investigation 34:4, pages 241-249.
Crossref
Crossref
Wakaya Fujiwara, Hideo Izawa, Gen Ukai, Hiroatsu Yokoi, Daisuke Mukaide, Kohsuke Kinoshita, Shin-ichiro Morimoto, Junichi Ishii, Yukio Ozaki & Masanori Nomura. (2012) Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart and Vessels 28:3, pages 316-322.
Crossref
Crossref
Reinhard Ketelhut & Peter Bramlage. (2012) Candesartan Cilexetil/Hydrochlorothiazide Treatment in High-Risk Patients with Type 2 Diabetes Mellitus and Microalbuminuria. Clinical Drug Investigation 30:5, pages 301-311.
Crossref
Crossref
Peter Bramlage, Eleonore Schönrock & Peter Odoj. (2008) Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. BMC Cardiovascular Disorders 8:1.
Crossref
Crossref
Steven G Chrysant. (2008) Using Fixed-Dose Combination Therapies to Achieve Blood Pressure Goals. Clinical Drug Investigation 28:11, pages 713-734.
Crossref
Crossref
Antonio Coca. (2008) Economic Benefits of Treating High-Risk Hypertension with Angiotensin II Receptor Antagonists (Blockers). Clinical Drug Investigation 28:4, pages 211-220.
Crossref
Crossref
J. M. Flack. (2007) Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. International Journal of Clinical Practice 61:12, pages 2093-2102.
Crossref
Crossref
Cleber E. Teixeira & R. Clinton Webb. (2005) Targeting the vascular RhoA–Rho-kinase signaling pathway in hypertension. Drug Discovery Today: Therapeutic Strategies 2:3, pages 193-199.
Crossref
Crossref